Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection.
Liu CH, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Chang YP, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH.
Liu CH, et al. Among authors: chang yp.
J Hepatol. 2024 Oct 3:S0168-8278(24)02578-9. doi: 10.1016/j.jhep.2024.09.038. Online ahead of print.
J Hepatol. 2024.
PMID: 39368711